On April 10, 2023, Shalini Sharp notified the Board of Directors (the “Board”) of Sutro Biopharma, Inc. (the “Company”) of her resignation as a Class III director and as the Chair of the Audit Committee of the Board (the “Audit Committee”), effective immediately (the “Resignation”).
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Shalini Sharp resigned as Class III Director and Chair of the Audit Committee at SUTRO BIOPHARMA, INC..
Action
resigned
Role
Class III Director and Chair of the Audit Committee
Exact text from the filing
On April 10, 2023, Shalini Sharp notified the Board of Directors (the “Board”) of Sutro Biopharma, Inc. (the “Company”) of her resignation as a Class III director and as the Chair of the Audit Committee of the Board (the “Audit Committee”), effective immediately (the “Resignation”).
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.